\
&
Contact us
Published on | 2 years ago
ProgrammesThe European Union and the Republic of Korea announce support for four jointly funded projects in semiconductors as a deliverable of the EU-Republic of Korea Digital Partnership.
The projects will advance heterogeneous integration technologies i.e. technologies combining multiple components onto one chip as well as neuromorphic computing technologies i.e. technologies imitating the functioning of the human brain.
The projects will bring together research and innovation partners from the EU and the Republic of Korea to set up joint research teams, provide shared access to cutting-edge facilities and infrastructures and organise knowledge exchange through events.
The selected joint EU-ROK projects are:
These are 3-year projects co-funded by the Chips Joint Undertaking under Horizon Europe, and the National Research Foundation of Korea (NRF).
For more information on the projects please consult the European Commission's news article.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
Agro-Food, Environment Missions
The FOREST Partnership has opened a call for experts read more
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.